Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cybin Inc. - Common Stock (NQ:HELP)

4.800 +0.480 (+11.11%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 753,870
Open 4.350
Bid (Size) 4.800 (1,000)
Ask (Size) 4.830 (400)
Prev. Close 4.320
Today's Range 4.350 - 4.865
52wk Range 4.290 - 8.970
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PsychedelicNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Jill Conwell as Chief People Officer
Via Investor Brand Network
News headline image
Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer
From Helus Pharma
Via GlobeNewswire

Performance

YTD
-37.9%
-37.9%
1 Month
-36.9%
-36.9%
3 Month
-37.9%
-37.9%
6 Month
-37.9%
-37.9%
1 Year
-37.9%
-37.9%

More News

Read More
News headline image
HELP Stock Crashes On Anxiety Trial Results, But Here’s Why Jefferies Sees Up To 200% Upside ↗
Via Stocktwits
News headline image
Dow Futures Hold Ground After 800-Point Selloff As Oil Surge Hits Wall Street: Why MRVL, USO, COST, HELP Are Trending After-Hours ↗
Via Stocktwits
Topics ETFs Stocks
BioMedNewsBreaks — Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Positive Phase 2 Results for HLP004 in Generalized Anxiety Disorder
Via Investor Brand Network
News headline image
Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion
Via FinancialNewsMedia
News headline image
HELP Stock Tanks 22% Despite Strong Phase 2 Results For Anxiety Treatment: Retail Buys The Dip Ignoring Market’s Pessimism ↗
Via Stocktwits
News headline image
Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder
From Helus Pharma
Via GlobeNewswire
TinyGemsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Dr. Freda Lewis-Hall to Board and Scientific Advisory Committee Chair
Via Investor Brand Network
News headline image
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
Via FinancialNewsMedia
News headline image
Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee
Via FinancialNewsMedia
News headline image
Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee
From Helus Pharma
Via GlobeNewswire
News headline image
Magic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast Raise ↗
Via MarketBeat
News headline image
HELP Stock Rallies After Experimental Depression Drug Reduces Symptoms In Study: Retail Thinks Its ‘Time To Buy More’ ↗
Via Stocktwits
PsychedelicNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Positive Phase 2a SPL026 Data Published in Nature Medicine
Via Investor Brand Network
News headline image
Nature Medicine Publishes Helus Pharma’s Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder
From Helus Pharma
Via GlobeNewswire
BioMedNewsBreaks — Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Q3 2025 Results, Advances Phase 3 and Phase 2 Programs
Via Investor Brand Network
Topics Intellectual Property
News headline image
HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
From Helus Pharma
Via GlobeNewswire
BioMedNewsBreaks — Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Michael Cola as Chief Executive Officer
Via Investor Brand Network
Topics Intellectual Property
News headline image
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market
Via FinancialNewsMedia
News headline image
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
Via FinancialNewsMedia
Topics Intellectual Property
News headline image
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
From Helus Pharma
Via GlobeNewswire

Frequently Asked Questions

Is Cybin Inc. - Common Stock publicly traded?
Yes, Cybin Inc. - Common Stock is publicly traded.
What exchange does Cybin Inc. - Common Stock trade on?
Cybin Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Cybin Inc. - Common Stock?
The ticker symbol for Cybin Inc. - Common Stock is HELP on the Nasdaq Stock Market
What is the current price of Cybin Inc. - Common Stock?
The current price of Cybin Inc. - Common Stock is 4.800
When was Cybin Inc. - Common Stock last traded?
The last trade of Cybin Inc. - Common Stock was at 03/31/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.